期刊名称：EXPERT OPINION ON DRUG SAFETY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Expert Opinion on Drug Safety ranks #107 of 236 in the Pharmacology & Pharmacy category in the 2009 ISI Journal Citation Reports.
Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development.
The Editors welcome:
Reviews covering occurrence, management and prevention of drug-associated adverse events; risk-benefit analyses of individual drugs and drug classes; safety in 'at-risk' patient populations; comparative tolerability studies; pharmacovigilance and pharmacoepidemiological studies
Drug Safety Evaluations reviewing the safety data on a particular drug
Original Research papers reporting the results of post-marketing surveillance and other safety studies looking at specific drugs, populations and outcomes; methods for the detection and evaluation of drug-associated adverse events
The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in monitoring drug safety.
Indexing
Chemical Abstracts (CODEN: EODSA9), EMBASE/Excerpta Medica, Index Medicus/Medline, Science Citation Index Expanded™
Instructions to Authors
Instructions for authors can be found at the links below:
Original Research
Drug Safety Evaluations
Reviews and other article types
Letters to the Editor
To submit a manuscript click here.
For full details of our editorial policies, including NIH-funded papers, please refer to our policy document and resources for authors.
Original research and other unsolicited articles
The Commissioning Editor, under the advice of the Editorial Board, solicits articles published in Expert Opinion on Drug Safety. However, the submission of Original Research and other unsolicited articles is welcomed, for which we offer the following service options:
FastTrack is the ultra-rapid publication service option offering prioritised peer review and expedited publication of manuscripts (submission to online publication in 5-7 weeks).
RapidTrack is the other prioritised option, offering submission to online publication in 10-12 weeks. A publication support fee is required for these service levels.
StandardTrack offers a non-prioritised service, where accepted manuscripts achieve submission to online publication in up to 20 weeks. There are no publication fees for this service.
Pre-submission contact
Expert Opinion on Drug Safety welcomes authors contacting the Editorial Offices ahead of formal submission and specially encourages prior contact for FastTrack submissions where a particular publication deadline is desired. If you are interested in submitting an article, please contact Elizabeth Knowles.
Peer review
All manuscripts are subject to confidential and anonymous (double-blinded) peer review by two independent referees. Comments remain confidential and are shared only with the corresponding author or submitting party. For our peer review guidelines, please click here. For Original Research peer review guidelines, please click here.
Editorial Board
Commissioning Editor: Misty Bond
Production Editor: Sumayya Patel
Drug Safety Evaluations Editor: Misty Bond
Original Research Editor: Elizabeth Knowles
| 
